Lumena CEO, Mike Grey, says the recent $23 million in Series A financing will fund the clinical development of LUM001, its lead product candidate for the treatment of a disorder called cholestatic liver disease.

Lumena CEO, Mike Grey, says the recent $23 million in Series A financing will fund the clinical development of LUM001, its lead product candidate for the treatment of a disorder called cholestatic liver disease. Photo by Melissa Jacobs.

Lumena Pharmaceuticals Inc...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • NEW: San Diego 500 — influential business leaders you need to know
Yours for only $129